Alzheon Initiates Phase 2 and 3 Open-Label Extensions for Alzheimer Agent ALZ-801.

Published Date: 05 May 2024

After completing 156 weeks of treatment, participants in the phase 2 biomarker trial were offered the opportunity to enrol in a 52-week extension to monitor various outcomes such as safety, evaluations of plasma biomarkers, and cognitive effects.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot